{"id":852037,"date":"2025-05-16T16:38:32","date_gmt":"2025-05-16T20:38:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"modified":"2025-05-16T16:38:32","modified_gmt":"2025-05-16T20:38:32","slug":"nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","title":{"rendered":"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Fort Lee, NJ, May  16, 2025  (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.<\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:59.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Event<\/td>\n<td style=\"width:563.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">3rd Annual H.C. Wainwright BioConnect Investor Conference<\/td>\n<\/tr>\n<tr>\n<td style=\"width:59.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Date<\/td>\n<td style=\"width:563.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">May 20<sup>th<\/sup>, 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:59.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Time<\/td>\n<td style=\"width:563.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">10:30 \u2013 11:00 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td style=\"width:59.67px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Link<\/td>\n<td style=\"width:563.67px;border-right: solid black 1pt;border-bottom: solid black 1pt\">Nuvectis   Pharma Presentation <a href=\"https:\/\/journey.ct.events\/view\/944d9d68-9ec8-4d34-983a-53245ca714c0\" rel=\"nofollow\" target=\"_blank\">Webcast Link<\/a><\/td>\n<\/tr>\n<\/table>\n<p>\n        <b>About Nuvectis Pharma, Inc.<\/b>\n      <\/p>\n<p>Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900&#8217;s unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.<\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Ron Bentsur<br \/>Chairman, Chief Executive Officer and President<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wKf7KlEASi3L0FC78MNak1YiCzb9fBwiIZAsj4v5x70onNj-jagxExEAmduYbZ-oT_qtrDY1IQrlAtgzN2LYKEDXzw6i3KZXfqcTfxFNGtM=\" rel=\"nofollow\" target=\"_blank\">rbentsur@nuvectis.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Media Relations Contact<\/strong><br \/>\n        <br \/>Kevin Gardner<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AqZ6lDlnhCzJaXcOLRmviuQP7iZCFTrerR8MWHPHL-ttW4yZI2ey8QhkBBAL_K20FEeycccKbEn-7Im5QHwEQTiVD5pDaojFMlZU4RZlE36AYsv9kZKRJoGVJSVSinrF\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a>\u00a0<\/p>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmViMDkyM2MtOWJiZC00YmQzLWJjNjMtYWE5ZDU4ZWM0MzY1LTUwMDA4MjgxNy0yMDI1LTA1LTE2LWVu\/tiny\/Nuvectis-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event 3rd Annual H.C. Wainwright BioConnect Investor Conference Date May 20th, 2025 Time 10:30 \u2013 11:00 a.m. ET Link Nuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-852037","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event 3rd Annual H.C. Wainwright BioConnect Investor Conference Date May 20th, 2025 Time 10:30 \u2013 11:00 a.m. ET Link Nuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The &hellip; Continue reading &quot;Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T20:38:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference\",\"datePublished\":\"2025-05-16T20:38:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"wordCount\":253,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"name\":\"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==\",\"datePublished\":\"2025-05-16T20:38:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","og_description":"Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event 3rd Annual H.C. Wainwright BioConnect Investor Conference Date May 20th, 2025 Time 10:30 \u2013 11:00 a.m. ET Link Nuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The &hellip; Continue reading \"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-16T20:38:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference","datePublished":"2025-05-16T20:38:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"wordCount":253,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","name":"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==","datePublished":"2025-05-16T20:38:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQzNyM2OTQ2OTc1IzUwMDA4MjgxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=852037"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852037\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=852037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=852037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=852037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}